Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab

  title={Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab},
  author={T. Brand and E. F. Dunn and M. Iida and R. Myers and Kellie T. Kostopoulos and C. Li and Chimera R. Peet and D. L. Wheeler},
  journal={Cancer Biology & Therapy},
  pages={436 - 446}
  • T. Brand, E. F. Dunn, +5 authors D. L. Wheeler
  • Published 2011
  • Medicine
  • Cancer Biology & Therapy
  • The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclonal antibodies (panitumumab, and cetuximab) and three tyrosine kinase inhibitors (erlotinib, gefitinib, and lapatinib). Both strategies of EGFR inhibition have demonstrated clinical successes, however many tumors remain non-responsive or acquire… CONTINUE READING
    15 Citations
    Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    • 44
    Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
    • 55
    AXL mediates resistance to cetuximab therapy.
    • 122
    • PDF
    Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
    • 20
    • PDF
    Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
    • 29
    Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol
    • 10
    • PDF
    Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
    • 2


    Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    • A. Bardelli, S. Siena
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 606
    Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    • 218
    • PDF